Advances in the treatment of multiple myeloma: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤

ABSTRACT

Multiple myeloma (MM) is the second most common hematological malignancy.In the 56th American Society of Hematology (ASH) annual meeting,there are mainly five hot and key topics focusing on development of MM treatment,including when is the opportunity of transplant-eligible patients in the era of novel therapy? Should continuous therapy be the standard therapeutic approach in MM? What is a practical approach to relapsed MM? How should the recurrence/refractory MM patients be managed and treated? And what are the approved agents and novel agents?